Thermo Fisher Scientific Inc. (NYSE:TMO) Receives Consensus Rating of “Buy” from Brokerages

Share on StockTwits

Shares of Thermo Fisher Scientific Inc. (NYSE:TMO) have earned an average recommendation of “Buy” from the fifteen brokerages that are covering the firm, MarketBeat reports. Two research analysts have rated the stock with a hold recommendation and thirteen have given a buy recommendation to the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $303.17.

Several research firms have recently commented on TMO. Barclays set a $330.00 price objective on Thermo Fisher Scientific and gave the stock a “buy” rating in a report on Monday, July 15th. UBS Group raised their target price on Thermo Fisher Scientific from $305.00 to $320.00 and gave the stock a “buy” rating in a research note on Thursday, May 23rd. Credit Suisse Group reissued a “buy” rating and issued a $310.00 target price on shares of Thermo Fisher Scientific in a research note on Wednesday, July 31st. BTIG Research raised their target price on Thermo Fisher Scientific to $320.00 and gave the stock a “buy” rating in a research note on Thursday, May 23rd. Finally, Argus raised their target price on Thermo Fisher Scientific from $285.00 to $310.00 and gave the stock a “buy” rating in a research note on Wednesday, May 1st.

In other Thermo Fisher Scientific news, Director C Martin Harris sold 275 shares of Thermo Fisher Scientific stock in a transaction that occurred on Wednesday, June 5th. The stock was sold at an average price of $270.73, for a total transaction of $74,450.75. Following the sale, the director now directly owns 6,433 shares of the company’s stock, valued at approximately $1,741,606.09. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Marc N. Casper sold 50,000 shares of Thermo Fisher Scientific stock in a transaction that occurred on Tuesday, July 30th. The shares were sold at an average price of $284.83, for a total value of $14,241,500.00. Following the sale, the chief executive officer now directly owns 342,193 shares in the company, valued at $97,466,832.19. The disclosure for this sale can be found here. Insiders sold 52,775 shares of company stock worth $14,986,676 over the last three months. 0.45% of the stock is owned by insiders.

A number of institutional investors have recently bought and sold shares of TMO. Cohen Lawrence B lifted its holdings in shares of Thermo Fisher Scientific by 2.0% during the second quarter. Cohen Lawrence B now owns 10,185 shares of the medical research company’s stock valued at $2,991,000 after purchasing an additional 195 shares during the last quarter. Private Trust Co. NA raised its holdings in Thermo Fisher Scientific by 66.7% in the 2nd quarter. Private Trust Co. NA now owns 3,273 shares of the medical research company’s stock worth $961,000 after acquiring an additional 1,310 shares during the last quarter. Parallel Advisors LLC raised its holdings in Thermo Fisher Scientific by 4.4% in the 1st quarter. Parallel Advisors LLC now owns 9,416 shares of the medical research company’s stock worth $2,578,000 after acquiring an additional 393 shares during the last quarter. Barrett Asset Management LLC raised its holdings in Thermo Fisher Scientific by 0.4% in the 1st quarter. Barrett Asset Management LLC now owns 111,500 shares of the medical research company’s stock worth $30,520,000 after acquiring an additional 395 shares during the last quarter. Finally, Gateway Investment Advisers LLC raised its holdings in Thermo Fisher Scientific by 45.5% in the 2nd quarter. Gateway Investment Advisers LLC now owns 38,146 shares of the medical research company’s stock worth $11,203,000 after acquiring an additional 11,928 shares during the last quarter. 88.21% of the stock is currently owned by institutional investors and hedge funds.

NYSE TMO traded down $3.23 during trading hours on Wednesday, reaching $271.94. 1,405,801 shares of the stock traded hands, compared to its average volume of 1,600,072. The firm has a 50 day moving average price of $287.70. Thermo Fisher Scientific has a 1 year low of $208.34 and a 1 year high of $305.45. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.07 and a current ratio of 1.49. The firm has a market cap of $110.68 billion, a P/E ratio of 24.46, a price-to-earnings-growth ratio of 1.81 and a beta of 1.11.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Wednesday, July 24th. The medical research company reported $3.04 earnings per share for the quarter, beating the Zacks’ consensus estimate of $3.01 by $0.03. The business had revenue of $6.32 billion for the quarter, compared to the consensus estimate of $6.31 billion. Thermo Fisher Scientific had a return on equity of 17.11% and a net margin of 14.24%. The company’s revenue for the quarter was up 3.9% on a year-over-year basis. During the same quarter last year, the business posted $2.75 earnings per share. On average, equities research analysts expect that Thermo Fisher Scientific will post 12.23 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, October 15th. Investors of record on Tuesday, September 17th will be paid a $0.19 dividend. The ex-dividend date of this dividend is Monday, September 16th. This represents a $0.76 annualized dividend and a dividend yield of 0.28%. Thermo Fisher Scientific’s payout ratio is presently 6.83%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.

Recommended Story: What are popular range trading strategies?

Analyst Recommendations for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.